BioNexus Gene Lab Corp.

Equities

BGLC

US0906282076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 15/05/2024 am IST			5-day change	1st Jan Change
0.5829 ^USD	+0.48%		-2.56%	+9.98%

16/04	BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/02	BioNexus Gene Lab Corp. Provides Information to Shareholders	CI

BioNexus Gene Lab : Submission of Matters to a Vote of Security Holders - Form 8-K

April 02, 2024 at 01:34 am IST

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Attachments

Original Link
Permalink

Disclaimer

BioNexus Gene Lab Corp. published this content on 01 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 April 2024 20:03:07 UTC.

Latest news about BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	16/04	CI
BioNexus Gene Lab Corp. Provides Information to Shareholders	01/03	CI
Certain Common Stock of BioNexus Gene Lab Corp. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.	18/01	CI
Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp	17/01	CI
BioNexus Gene Lab Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21/11	CI
Bionexus Gene Lab Corp. Announces Resignation of Wei Li Leong as Chief Financial Officer	03/11	CI
BioNexus Gene Lab Names Chi Yuen Leong as CEO	16/23/16	MT
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer	16/23/16	CI
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as A Director	16/23/16	CI
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer	11/23/11	CI
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Board of Directors	11/23/11	CI
BioNexus Gene Lab Corp. Announces Executive Changes	07/23/07	CI
Top Premarket Gainers	23/23/23	MT
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/23/16	CI
BioNexus Gene Lab Raises $5.8 Million from Public Share Offering	24/23/24	MT
BioNexus Gene Lab Corp.(NasdaqCM:BGLC) added to NASDAQ Composite Index	24/23/24	CI
Top Midday Gainers	21/23/21	MT
Wall Street Set to Open Higher, Investors Look to End Week on Positive Note	21/23/21	MT
Investors Look to Close Week on Positive Note as US Futures See Mixed Performance Premarket Friday	21/23/21	MT
Top Premarket Gainers	21/23/21	MT
BioNexus Gene Lab Corp. has completed an IPO in the amount of $5 million.	21/23/21	CI
BioNexus Gene Lab Shares Fall in Nasdaq Debut	21/23/21	MT
BioNexus Gene Lab Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
BioNexus Gene Lab Corp. has filed an IPO in the amount of $17.25 million.	14/23/14	CI

Chart BioNexus Gene Lab Corp.

Duration

Period

More charts

Company Profile

BioNexus Gene Lab Corp., through its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd., focuses on the wholesale of chemical raw material products. The Company is engaged in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. The Company is also engaged in the business of developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. Its non-invasive blood screening tests analyze changes in ribonucleic acid (RNA) to detect the risk potentiality of approximately 11 different diseases. It offers a range of fiberglass reinforced plastic (FRP) products, which include Polyester Resin SHCP 268, Polyester Resin 9509 and Polyester Resin 2802. The FRP and other raw materials it offers are used to produce a variety of goods, including handrails, bench tops, cleanroom panels, and covers for various instruments used in manufacturing.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIONEXUS GENE LAB CORP.	+9.98%	10.3M
MODERNA, INC.	+29.03%	49.18B
IQVIA HOLDINGS INC.	-0.10%	42.11B
LONZA GROUP AG	+43.45%	40.37B
CELLTRION, INC.	-5.26%	28.85B
ICON PUBLIC LIMITED COMPANY	+11.48%	26.09B
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	18.71B
BIO-TECHNE CORPORATION	+9.06%	13.26B
MEDPACE HOLDINGS, INC.	+30.01%	12.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	11.99B

Other Biotechnology & Medical Research